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of the dysnatremias’
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I wrote a letter to ask Kurtz and Nguyen1 to specify how
accurate their assessment of the equation [Naþ ]pw¼
1.11(NaeþKe)/TBW25.6 and its proposed augmentations
could possibly be: intervals of confidence for slope and
intercept. If these are undefined, I would assume that the
many equations could not be distinguished in clinical
practice, including the one with intercept¼ 0 and
slope¼ 1. The authors do not seem to know an answer to
that question. Boling and Lipkind provided an analysis of
the intercept measurement in the Edelman paper similar to
what I did, based on the original values and wrote: ‘ythe
degree of certainty regarding the magnitude of this
constant term is not great; the origin of regression lies
within the 99% confidence limits for the regression line,
and the 95% confidence limits (at X¼ 0) are 5.2 and
45.8’.2 I had 5.2 and 46.0 with present-day software.
As Edelman and co-workers described, this equation was
obtained by careful assessment of a great number of
patients by isotopic dilutions. These dilutions are not
simple, requiring 40 h for K and 24 h of observation for Na
(probably explaining that they were not frequently
performed in recent times) and the problem of knowing
when equilibrium is reached certainly is not straight-
forward and necessarily mixes with subtle definitions of
osmotically active and inactive moieties. The suggestion
that osmotic balance is rapidly attained is not contested,
but steady state must be of interest when assessing the
exchangeability of electrolytes during 40 h of equilibrium.
Recent experimental studies arguing about the status of
osmotic inactivation and also observations from sports
medicine show that quite large amounts of Na and
K can behave unpredictably.3–5 Hence, even though the
authors cite a number of situations wherein they have
difficulties in understanding [Na], I cannot see how they
conclude that a and b in [Naþ ]pw¼ a(NaeþKe)/TBWb are
primarily to fault when (NaeþKe)/TBW are not measured
in any of these studies.
I certainly agree with the authors that the work of
Edelman et al. was second to none, and really wrote my letter
to ask for more of that kind instead of math work. Edelman
et al. carefully specified the uncertainty of the estimates, as
I wrote, and even gave the individual data (from which, by
the way, it can be verified that minor miscalculations
occurred in patient numbers 25 and 37 (heart disease) – but,
rest assured, removing them changes nothing). However, a
complicated thing such as measuring deuterium enrichment
has changed during the years, and the falling drop method as
used by Edelman et al. has since been surpassed.6 It is true
that Edelman et al. made a correction for imprecision in
measurements to augment the correlation coefficient, but it
is wrong as stated by Kurtz et al. in their original paper that
this bears directly over to the regression – which was carried
out simply by least squares. The authors are right, however,
that uncertainty attenuates the regression, but I doubt it is
easy to say by how much. One of the most important
determinants will be the spread in independent values –
which is quite large in the original Edelman data, as
mentioned by Boling et al.1 The Passing–Bablok regression,
now introduced by Kurtz et al. was described in 1983 and
not mentioned by Edelman in 1958 (which was the
question). However, Kurtz et al. may well be right that the
true slope in [Naþ ]pw¼ a(NaeþKe)/TBWb often is more
than 1 and the intercept often different from 0. The issue was
if 11 new equations were separable, however. It is true that to
all this must be added problems of individual patient frailty
and autocorrelations between repeated measurements in
each patient and more. I did not miss the point, that
Edelman made a brilliant cross-sectional study. This only
further strengthens the demand for data rather than
speculation when trying to untangle this difficult subject.
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Measurements, at least of whole-body balances and
exchangeable cations, are needed to understand when and
why and how the famous Edelman equation needs
augmentation. Until then, it might as well be kept simple,
yes, that was my point. Like others, I have found good use
of the simple form,7 but I am prepared that it will not
always suffice.8
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Lanthanum data in perspective
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To the Editor: Based on rodent tissue deposition data,
Slatopolsky et al.1 allude to potential hepatic effects with
long-term use of lanthanum carbonate in end-stage renal
disease patients. Continuing vigilance and safety monitoring
are essential for any new drug, but existing animal and
human safety data do not indicate a specific concern in
relation to the liver toxicity for lanthanum. The liver is the
primary excretory organ for lanthanum, which is highly
protein bound. It is taken up and eliminated by the
transferrin receptor–endocytosis–lysosomal–biliary canalicu-
lar system.2 Thus, lanthanum appears to have an innocent
localization, being confined to the hepatic endosomal/
lysosomal compartment during passage through the liver
into bile. As a result of this transcellular transport mechan-
ism, lanthanum carbonate given to rats at a dose of 1500 mg/
kg body weight for 78 weeks resulted in a low steady-state
concentration of 2.471.5 mg/g (17711 nmol/g) of liver
tissue, from week 26 onwards. In comparison, the steady-
state liver concentration of copper and iron in normal
man vary around 32 mg/g (503 nmol/g) and 560 mg/g
(710 000 nmol/g), respectively. Published tissue deposition
studies in uremic rats1,2 have consistently demonstrated that
liver exposure is at trace levels (o2.6 mg/g (o19 nmol/g)),
with no evidence of adverse histologic or ultrastuctural
changes reported. Stringent genetic toxicity and lifetime
rodent safety studies conducted at high doses have similarly
failed to identify any toxic, genotoxic, or carcinogenic
potential in relation to the liver.3 Controlled clinical studies
to date have not shown a signal for adverse hepatic effects
owing to lanthanum treatment. In a recent analysis of
hepatobiliary adverse events and liver function data from
over 2000 dialysis patients participating in Phase III trials of
lanthanum carbonate (doses up to 3.75 g/day) for up to 2
years, we found no increase in hepatobiliary adverse events or
raised liver enzyme activities resulting from treatment
(Table 1).4
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Table 1 | Liver enzyme activities (mean7s.d.) after 1 and 2
years of treatment with lanthanum carbonate or standard
therapy
Lanthanum
carbonate
(n=682)
Standard
therapy
(n=677) P-value
1 year
ALT (U/l) 17.8712.2 17.3712.5 —
Change from baseline 1.3715.9 0.03713.0 0.197
GGT (U/l) 43.9781.7 48.6776.2 —
Change from baseline 0.5747.1 4.9744.4 0.107
2 years
ALT (U/l) 17.0710.4 15.5717.6 —
Change from baseline 2.17715.1 1.16711.0 0.421
GGT (U/l) 42.8784.2 44.6768.1 —
Change from baseline 0.6749.7 2.8743.5 0.425
ALT, alanine aminotransferase; GGT, gamma-glutamyl transpeptidase.
Patients received lanthanum carbonate (doses up to 3 g/day) or standard therapy
(previous phosphate binder) in a randomized trial for 2 years. Liver-related adverse
events occurred in 28 patients (4%) on lanthanum carbonate and 63 patients (7%)
on standard therapy, of which none was considered likely to be related to treatment
(values adjusted for treatment exposure).
Normal values: ALTo30 U/l (men) and o19 U/l (women); GGT 0–51 U/l.
Statistical comparisons were made using a mixed effect model to compare the
change from baseline. Reproduced from Hutchison et al.4
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